548 related articles for article (PubMed ID: 8930810)
41. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram.
Shahid M; Nicholson CD
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):698-705. PubMed ID: 1710786
[TBL] [Abstract][Full Text] [Related]
42. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E
J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853
[TBL] [Abstract][Full Text] [Related]
43. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
[TBL] [Abstract][Full Text] [Related]
44. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
45. [The role of the components of the cyclic nucleotide system in N-nitrosodiethylamine-induced hepatic carcinogenesis in rats].
Antonenko SG; Berdinskikh NK; Mishnaevskaia EG
Eksp Onkol; 1990; 12(5):18-21. PubMed ID: 2171896
[TBL] [Abstract][Full Text] [Related]
46. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.
Zhou L; Thompson WJ; Potter DE
Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1745-52. PubMed ID: 10393044
[TBL] [Abstract][Full Text] [Related]
47. Changes in phosphodiesterase activity in the developing rat submandibular gland.
Tanaka S; Shimooka S; Shimomura H
Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
[TBL] [Abstract][Full Text] [Related]
48. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
49. Negative functional effects of cyclic GMP are altered by cyclic AMP phosphodiesterases in rabbit cardiac myocytes.
Weiss HR; Lazar MJ; Punjabi K; Tse J; Scholz PM
Eur J Pharmacol; 2003 Nov; 481(1):25-31. PubMed ID: 14637171
[TBL] [Abstract][Full Text] [Related]
50. Regulation of multiple forms of cyclic nucleotide phosphodiesterase from bovine hypothalamus: new factors modulating enzyme activity.
Galoyan AA; Gurvitz BYa
Neurochem Res; 1985 Nov; 10(11):1467-81. PubMed ID: 3003614
[TBL] [Abstract][Full Text] [Related]
51. Interaction of cyclic GMP and cyclic AMP during neutrophil migration: involvement of phosphodiesterase type III.
VanUffelen BE; de Koster BM; Elferink JG
Biochem Pharmacol; 1998 Oct; 56(8):1061-3. PubMed ID: 9776319
[TBL] [Abstract][Full Text] [Related]
52. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
53. Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells.
Yao J; Hiramatsu N; Zhu Y; Morioka T; Takeda M; Oite T; Kitamura M
J Am Soc Nephrol; 2005 Jan; 16(1):58-67. PubMed ID: 15537869
[TBL] [Abstract][Full Text] [Related]
54. [Phosphodiesterases of cyclic GMP].
Wróblewska H; Gorczyca WA
Postepy Hig Med Dosw; 2001; 55(5):611-27. PubMed ID: 11795198
[TBL] [Abstract][Full Text] [Related]
55. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
Harrison SA; Reifsnyder DH; Gallis B; Cadd GG; Beavo JA
Mol Pharmacol; 1986 May; 29(5):506-14. PubMed ID: 3010079
[TBL] [Abstract][Full Text] [Related]
56. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
[TBL] [Abstract][Full Text] [Related]
57. A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5).
Corbin JD; Beasley A; Turko IV; Haik TL; Mangum KA; Wells JN; Francis SH; Sekhar KR
Cell Biochem Biophys; 1998; 29(1-2):145-57. PubMed ID: 9631243
[TBL] [Abstract][Full Text] [Related]
58. Differential susceptibility to biological detergents of the particulate cGMP-stimulated phosphodiesterase from rat heart: preservation of the allosteric properties of the solubilized enzyme.
Timouyasse L; Prigent AF; Némoz G; Lagarde M; Pachéco H
Biochem Int; 1989 Aug; 19(2):287-99. PubMed ID: 2554908
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
60. High activity of low-Michaelis-Menten constant 3', 5'-cyclic adenosine monophosphate-phosphodiesterase isozymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus.
Takeda S; Lin CT; Morgano PG; McIntyre SJ; Dousa TP
Endocrinology; 1991 Jul; 129(1):287-94. PubMed ID: 1647298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
